Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8228748 | 0.87 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1 | |
| SCHEMBL23918942 | 0.77 | NR1I2 (0.36) | NR1I2CYSLTR2CYSLTR1LMNASLC2A1 | |
| SCHEMBL23918943 | 0.74 | NR1I2 (0.35) | NR1I2CYSLTR2CYSLTR1LMNACSNK1E | |
| SCHEMBL23918554 | 0.71 | NR1I2 (0.43) | NR1I2LMNASLC2A1CSNK1E | |
| SCHEMBL27599791 | 0.68 | CYSLTR2 (0.42) | CYSLTR2CYSLTR1 | |
| SCHEMBL7648740 | 0.67 | CYSLTR2 (0.48) | NR1I2CYSLTR2CYSLTR1CSNK1E | |
| SCHEMBL6547454 | 0.67 | CYSLTR2 (0.48) | NR1I2CYSLTR2CYSLTR1CSNK1E | |
| SCHEMBL11177011 | 0.67 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1CSNK1E | |
| SCHEMBL23918902 | 0.67 | NR1I2 (0.35) | NR1I2LMNADNM1 | |
| SCHEMBL21423056 | 0.67 | MC4R (0.37) | NR1I2CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | EP300, CREBBP, HDAC11 | NR1I2 602/4885CYSLTR2 1923/4885CYSLTR1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.